Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Elanco Animal Health Incorporated regarding a class action lawsuit alleging misleading statements and omissions related to product safety and approval timelines [1][2]. Group 1: Allegations - The complaint claims that Elanco misrepresented the safety of Zenrelia, an oral inhibitor for canine dermatology, suggesting it was safer than it actually is [1]. - It is alleged that Elanco is unlikely to meet its previously stated timeline for the U.S. approval and commercial launch of Zenrelia and Credelio Quattro, a parasiticide for dogs [1]. - The company's business and financial prospects were reportedly overstated due to these misleading statements, leading to a misrepresentation of the company's public statements [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as November 7, 2023, to June 26, 2024, and shareholders are encouraged to register for participation [1][2]. - The deadline for shareholders to seek lead plaintiff status is December 6, 2024, with no cost or obligation to participate in the case [2]. Group 3: Law Firm Background - The Gross Law Firm is recognized nationally for class action lawsuits, focusing on protecting investors from deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Elanco Animal Health securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class action lawsuit against Elanco alleges that the company made false and misleading statements regarding the safety and approval timelines of its products, Zenrelia and Credelio Quattro, which led to overstated business prospects [3] - Investors who purchased Elanco securities between November 7, 2023, and June 26, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][3] - The deadline to move the Court to serve as lead plaintiff is December 6, 2024, and a lead plaintiff acts on behalf of other class members in directing the litigation [1] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [2] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [2] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [2]

NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/?id=109169& ...

LOS ANGELES, Oct. 23, 2024 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointme ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities who purchased or otherwise acquired Elanco Animal Health Incorporated (NYSE: ELAN) securities between November 7, 2023 and June 26, 2024. Elanco is an animal health company that develops, manufactures, and markets products for pets and farm animals. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. T ...

Core Viewpoint - A class action lawsuit has been filed against Elanco Animal Health Incorporated for allegedly misleading investors regarding the safety and approval timelines of its drugs Zenrelia and Credelio Quattro [1][3]. Group 1: Lawsuit Details - The lawsuit was filed in the U.S. District Court for the District of Maryland on behalf of investors who acquired Elanco securities between November 7, 2023, and June 26, 2024 [1]. - Investors have until December 6, 2024, to apply to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Product Approval Timeline - Elanco initially set a timeline for U.S. approval of Zenrelia and Credelio Quattro for the first half of 2024, but later delayed the approval to the third quarter of 2024 for both drugs [1][2]. - A press release on June 27, 2024, indicated that Zenrelia would likely include a boxed warning on safety, which could slow product adoption and reduce the safe administration days for vaccinated dogs by approximately 25% [2]. - Following the announcement, Elanco's share price fell by $3.69, or about 20.53%, from $17.97 to $14.28 per share [2]. Group 3: Allegations in the Lawsuit - The lawsuit alleges that Elanco made false or misleading statements regarding the safety of Zenrelia and the likelihood of meeting its previously issued timelines for the approval and launch of both Zenrelia and Credelio Quattro [3].

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...